生命科学资讯

Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Old school healthcare is warming up to tech

Did Lonza's Inhalable Biologics Push with Iconovo Just Reframe Lonza Group's (SWX:LONN) Investment Narrative? - simplywall.st

[Form 4] AGILENT TECHNOLOGIES, INC. Insider Trading Activity - Stock Titan

Prime Medicine reverses course to seek FDA approval of shelved therapy

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

FDA details rationale for rejecting rare disease gene therapy from Regenxbio

WAT - Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results - ADVFN Ltd

FDA explains how some copycat drugs can still win three years of exclusivity

Agilent Technologies (A) Analyst Rating Update: Morgan Stanley L - GuruFocus

[144] THERMO FISHER SCIENTIFIC INC. SEC Filing - Stock Titan

Kyowa Kirin abandons touted eczema drug following safety review

Morgan Stanley Lowers Agilent Technologies (NYSE:A) Price Target to $160.00 - MarketBeat

Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm

GSK nabs two Frontier Biotech siRNA assets in $1B deal

Wave of deals lifts large-cap biopharma stocks

US taking a closer look at China biotech subsidies